Document 0462
 DOCN  M9550462
 TI    Treatment options in zidovudine intolerance or failure.
 DT    9505
 AU    Abrams DI; Terry Beirn Community Programs for Clinical Research on
       AIDS,; University of California, San Francisco.
 SO    AIDS. 1994 Sep;8 Suppl 3:S3-7. Unique Identifier : AIDSLINE MED/95142951
 AB    AIM: To compare the efficacy and safety of didanosine and zalcitabine in
       patients who could not tolerate zidovudine or who had failed to respond
       adequately. PATIENTS AND METHODS: A multicentre, randomly allocated,
       open-label clinical trial was set up with 230 patients treated with
       didanosine and 237 treated with zalcitabine. All had previously been
       treated unsuccessfully with zidovudine. The patients were followed for
       at least 1 year, with an average of 16 months. RESULTS: Disease
       progression or death occurred in 157 patients taking didanosine and 152
       taking zalcitabine. There appeared to be a slight trend in favour of
       survival in the latter group. CONCLUSIONS: There is an urgent need for
       more effective and better tolerated antiretroviral agents in the
       treatment of HIV infection. Zalcitabine is at least as effective as
       didanosine and may provide a survival advantage in patients treated
       unsuccessfully with zidovudine.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY  Adult
       Comparative Study  Didanosine/TOXICITY/*THERAPEUTIC USE  Female
       Follow-Up Studies  Human  Male  Support, U.S. Gov't, P.H.S.  Survival
       Rate  Time Factors  Treatment Failure  Zalcitabine/TOXICITY/*THERAPEUTIC
       USE  Zidovudine/ADVERSE EFFECTS/*THERAPEUTIC USE  CLINICAL TRIAL
       JOURNAL ARTICLE  MULTICENTER STUDY  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).